金融界8月4日消息，上证指数低开高走，中证香港100医药卫生指数 (H100医药，L11185)报1091.30点。 从中证香港100医药卫生指数持仓样本的行业来看，化学药占比54.55%、生物药品占比19.02%、制药与 生物科技服务占比15.26%、医疗商业与服务占比11.18%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当对应的母指数调整样本时， 行业指数样本将相应调整。当样本公司有特殊事件发生，导致其行业归属发生变更时，将对指数进行相 应调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照 计算与维护细则处理。 本文源自：金融界 作者：行情君 数据统计显示，中证香港100医药卫生指数近一个月上涨20.90%，近三个月上涨36.74%，年至今上涨 88.77%。 据了解，中证香港100行业指数系列将中证香港100指数样本按中证行业分类标准进行分类，再以各自行 业 ...

从中证沪港深500医药卫生指数持仓的市场板块来看，香港证券交易所占比37.87%、上海证券交易所占 比33.61%、深圳证券交易所占比28.52%。 从中证沪港深500医药卫生指数持仓样本的行业来看，化学药占比36.20%、制药与生物科技服务占比 18.33%、生物药品占比18.14%、医疗器械占比11.07%、中药占比8.56%、医疗商业与服务占比7.70%。 资料显示，该指数系列样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五 的下一交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一 个定期调整日前，权重因子一般固定不变。特殊情况下将对该指数系列样本进行临时调整。当样本退市 时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处 理。当中证沪港深500指数、中证沪港深互联互通中小综合指数和中证沪港深互联互通综合指数样本发 生变动时，将进行相应调整。 金融界8月1日消息，上证指数下跌0.37%，中证沪港深500医药卫生指数 (沪港深500医药，H30463)下跌 1.74%，报8507.96点，成交额405.94亿元 ...

Core Points - The CSI Biopharmaceutical Theme 50 Index (CSI Pharma 50) has shown significant growth, with an increase of 8.88% over the past month, 15.61% over the past three months, and 12.91% year-to-date [1] - The index comprises 50 listed companies in the biopharmaceutical sector that exhibit high profitability, strong cash flow, and innovation capabilities, reflecting the overall performance of representative companies in this theme [1] Index Composition - The top ten weighted companies in the CSI Pharma 50 Index are: WuXi AppTec (17.54%), Hengrui Medicine (15.25%), Mindray Medical (11.6%), Aier Eye Hospital (4.96%), Kelun Pharmaceutical (3.32%), New Horizon (2.9%), Changchun High-tech (2.83%), Aimeike (2.28%), Huatai Medical (2.12%), and Baillie Gifford (2.05%) [1] - The index is evenly split between the Shenzhen Stock Exchange and the Shanghai Stock Exchange, each accounting for 50% of the holdings [1] Industry Breakdown - The industry composition of the CSI Pharma 50 Index is as follows: Chemical drugs (31.34%), Medical devices (25.53%), Pharmaceutical and biotechnology services (19.38%), Biopharmaceuticals (15.64%), Medical commerce and services (4.96%), and Traditional Chinese medicine (3.14%) [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2]

Core Viewpoint - The CSI 1000 Healthcare Index has shown significant growth, with a 4.34% increase over the past month, 12.39% over the last three months, and 16.26% year-to-date [1] Group 1: Index Performance - The CSI 1000 Healthcare Index is currently at 12,486.30 points [1] - The index is based on a sample of liquid and representative securities from each industry, providing diverse investment options [1] Group 2: Index Holdings - The top ten weighted stocks in the CSI 1000 Healthcare Index include: - Zai Lab (3.14%) - Tonghua Golden Horse (3.02%) - Borui Pharmaceutical (2.67%) - Zuoli Pharmaceutical (1.69%) - Rongchang Biologics (1.59%) - Zhaoyan New Drug (1.47%) - Yipinhong (1.44%) - Anke Biologics (1.42%) - Zhongsheng Pharmaceutical (1.42%) - Yifan Pharmaceutical (1.38%) [1] - The index's market distribution shows that the Shanghai Stock Exchange accounts for 55.72%, while the Shenzhen Stock Exchange accounts for 44.28% [1] Group 3: Industry Composition - The industry composition of the CSI 1000 Healthcare Index is as follows: - Chemical drugs: 35.86% - Medical devices: 19.60% - Traditional Chinese medicine: 17.00% - Biological drugs: 14.32% - Medical commerce and services: 7.53% - Pharmaceutical and biotechnology services: 5.69% [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2]

Group 1 - The core viewpoint of the article highlights the significant performance of the CESHKB index, which has seen substantial increases over various time frames, indicating a strong market trend in the biotechnology sector in Hong Kong [1][2]. - The CESHKB index rose by 3.66% to 7559.76 points, with a trading volume of 12.113 billion [1]. - Over the past month, the CESHKB index has increased by 15.96%, by 28.51% over the last three months, and has risen 62.76% year-to-date [1]. Group 2 - The CESHKB index is compiled by China Securities Index Co., Ltd. and aims to reflect the overall performance of biotechnology companies listed in Hong Kong [1]. - The index is based on a reference date of December 12, 2014, with a base point of 2000.0 [1]. - The top ten holdings of the CESHKB index include companies such as CanSino Biologics (10.79%), Innovent Biologics (10.03%), and BeiGene (9.56%) [1]. Group 3 - The market composition of the CESHKB index is entirely based on the Hong Kong Stock Exchange [2]. - In terms of industry distribution, biopharmaceuticals account for 56.98%, pharmaceutical and biotechnology services for 24.70%, chemical drugs for 16.03%, and medical devices for 2.29% [2].

Group 1 - The core viewpoint of the news is that the China Securities Medicine and Health Dividend Index has shown positive performance, with a 6.35% increase over the past month and a 5.98% increase over the past three months, while year-to-date it has risen by 1.32% [2] - The index is designed to reflect the overall performance of high dividend yield securities in various industries, using a dividend yield weighted calculation method [2] - The index's top ten holdings include Mingde Biological (4.22%), Huate Dain (3.3%), Lingrui Pharmaceutical (3.21%), and others, indicating a diverse portfolio within the healthcare sector [2] Group 2 - The index is composed of stocks with a cash dividend yield greater than 0.5% and ranks within the top 80% of average daily trading volume over the past year, with annual adjustments made to the sample [3] - The index's holdings are primarily in traditional Chinese medicine (36.05%), chemical drugs (22.28%), and medical services (17.54%), showcasing a focus on various segments of the healthcare industry [2] - The index is maintained with specific rules regarding sample adjustments, including a limit on the proportion of changes and conditions for excluding stocks that do not meet the criteria [3]

Group 1 - The core index of the CSI Hong Kong Stock Connect Medical Theme Index has shown a recent increase of 9.41% over the past month, while it has decreased by 0.61% over the last three months and increased by 18.99% year-to-date [1] - The index consists of 50 listed companies involved in medical devices, medical business and services, pharmaceuticals, and biotechnology services, reflecting the overall performance of the medical sector within the Hong Kong Stock Connect [1] - The top ten weighted companies in the index include WuXi Biologics (16.6%), JD Health (11.41%), Alibaba Health (7.52%), Sinopharm (5.68%), WuXi AppTec (5.51%), Weigao Group (3.66%), Genscript Biotech (3.55%), Innovent Biologics (2.4%), CanSino Biologics (2.23%), and MicroPort Scientific (2.2%) [1] Group 2 - The industry composition of the index shows that medical business and services account for 35.62%, pharmaceutical and biotechnology services for 31.58%, medical devices for 11.75%, chemical drugs for 10.53%, biological drugs for 10.09%, and traditional Chinese medicine for 0.42% [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or spin-offs [2]

Group 1 - The core viewpoint of the news is the performance of the CSI Hong Kong Stock Connect Biotechnology Theme Index, which has shown significant growth over various time frames, indicating a positive trend in the biotechnology sector within the Hong Kong stock market [1][2]. - The CSI Hong Kong Stock Connect Biotechnology Theme Index reported a value of 1276.34 points, with a 0.05% increase over the past month, a 31.09% increase over the past three months, and a 32.29% increase year-to-date [1]. - The index comprises 50 listed companies involved in biopharmaceuticals, pharmaceuticals, and biotechnology services, reflecting the overall performance of biotechnology theme stocks within the Hong Kong Stock Connect [1][2]. Group 2 - The top ten weighted companies in the index include: BeiGene (16.12%), WuXi Biologics (11.93%), Innovent Biologics (11.03%), CanSino Biologics (7.89%), CSPC Pharmaceutical Group (6.37%), China Biologic Products (5.62%), Hansoh Pharmaceutical (3.65%), Zai Lab (3.39%), WuXi AppTec (2.97%), and 3SBio (2.92%) [1]. - The index's holdings are entirely composed of stocks listed on the Hong Kong Stock Exchange, with a sector breakdown showing 52.26% in biopharmaceuticals, 25.22% in chemical drugs, 19.39% in pharmaceutical and biotechnology services, and 3.13% in medical devices [2].

Core Viewpoint - Tonghe Pharmaceutical reported a revenue of 759 million yuan for 2024, a year-on-year increase of 5.1%, and a net profit attributable to shareholders of 107 million yuan, up 0.6% [1] Group 1: Company Performance - The company's operating cash flow net amount reached 285 million yuan, growing by 74.2% [1] - The company focuses on the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates, with a leading production capacity and product quality in China [2][3] - The company has over 600 various types of enamel and metal reaction kettles, with a total volume exceeding 3 million liters [2] Group 2: Market Outlook - The global active pharmaceutical ingredient (API) market is expected to see significant growth, with approximately 300 billion USD worth of original drugs set to lose patent protection from 2019 to 2026, leading to a potential API market increase of nearly 200 billion yuan [2] - China is a major global producer and supplier of APIs, and the implementation of centralized procurement policies is expected to enhance the concentration of pharmaceutical companies and increase the space for import substitution [3] Group 3: Strategic Focus - The company emphasizes focusing on its core business, avoiding diversification, and aims to strengthen its position in the chemical pharmaceutical industry [4] - The average R&D investment over the past three years accounted for 8.34% of sales, with increased focus on various therapeutic areas [4] - The company plans to enhance domestic market development while maintaining a strong export focus, aiming for simultaneous sales in both domestic and international markets [5]

Group 1 - The core index of the CSI Hong Kong Stock Connect Medical Theme Index has shown a decline of 11.89% over the past month, an increase of 13.46% over the past three months, and a year-to-date increase of 8.75% [1] - The index consists of 50 listed companies involved in medical devices, medical services, pharmaceuticals, and biotechnology, reflecting the overall performance of the medical sector within the Hong Kong Stock Connect [1] - The index is based on a starting point of 1000.0 points as of December 31, 2018 [1] Group 2 - The top ten weighted companies in the index include WuXi Biologics (15.72%), JD Health (11.24%), Alibaba Health (7.31%), Sinopharm (5.92%), WuXi AppTec (5.0%), Kingstar BioTech (3.88%), Weigao Group (3.72%), CanSino Biologics (2.43%), MicroPort Medical (2.4%), and Innovent Biologics (2.35%) [1] - The index is exclusively composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Group 3 - The industry composition of the index includes 35.98% in medical services, 30.61% in pharmaceuticals and biotechnology, 12.17% in medical devices, 10.73% in chemical drugs, 10.09% in biological drugs, and 0.42% in traditional Chinese medicine [2] - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers and acquisitions [2]